Sort
78,016 grants matching “breast cancer”
INHIBITING MDSC BIOGENESIS TO AUGMENT IMMUNOTHERAPY EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER
$601,167Health Research, Inc. · · FY2021 · Defense Health Agency
Validation of a novel 3D culture platform for TNBC treatment selection
$601,157Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2023 · CA
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy
$601,146Nola M. Hylton · University Of California, San Francisco · R01 · FY2019 · CA
Modifiers of Cancer Risk in BRCA 1/2 Mutation Carriers
$601,094University Of Pennsylvania · R01 · FY2005 · CA
Damage-associated molecular patterns in chemotherapy toxicity
$601,091Eric Daniel Eisenmann · Ohio State University · R37 · FY2025 · CA
Primary Project
$601,082Eva M Sevick-Muraca · University Of Texas Hlth Sci Ctr Houston · U54 · FY2010 · CA
Sex Hormones in Pulmonary Arterial Hypertension
$601,064James E Loyd · Vanderbilt University Medical Center · P01 · FY2018 · HL
Small molecules targeting RuvBL complex for triple negative breast cancer
$601,059Xiangshu Xiao · Oregon Health & Science University · R01 · FY2023 · CA
Small molecules targeting RuvBL complex for triple negative breast cancer
$601,059Xiangshu Xiao · Oregon Health & Science University · R01 · FY2025 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer
$601,022Himisha Beltran · Dana-Farber Cancer Inst · R37 · FY2025 · CA
Centralization of Cancer Care: Implications for Access, Outcomes, and Disparities
$601,009Bruce L. Jacobs · University Of Pittsburgh At Pittsburgh · R37 · FY2025 · CA
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center
$600,941Jason Derek Merker · Univ Of North Carolina Chapel Hill · UG1 · FY2025 · CA
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
$600,913Efstathios Karathanasis · Case Western Reserve University · R01 · FY2023 · CA
Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice
$600,903Gregory R J Thatcher · University Of Illinois At Chicago · R01 · FY2018 · AG
Addressing Sexual Concerns in Breast Cancer Survivors: RCT of a Novel Couple-Based Intervention
$600,882Jennifer Barsky Reese · Research Inst Of Fox Chase Can Ctr · R01 · FY2022 · CA
Precision Imaging of Breast Cancer for Guiding Neoadjuvant Endocrine Therapy
$600,877Amy Fowler · University Of Wisconsin-Madison · R01 · FY2023 · CA
Commonly Used Medications and Risk of Colorectal Cancer Recurrence
$600,838Jessica Chubak · Kaiser Foundation Health Plan Of Washington · R01 · FY2013 · CA
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$600,798Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Evaluating an evidence-based family history screening program adapted to increase reach and uptake of screening for BRCA-associated cancers in rural public health clinics
$600,748Yue Guan · Emory University · R37 · FY2025 · CA
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
$600,681Melanie R Palomares · Beckman Research Institute/City Of Hope · R01 · FY2011 · CA
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors
$600,677Christopher I Li · Fred Hutchinson Cancer Research Center · R01 · FY2010 · CA
Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis
$600,660Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2014 · CA
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
$600,621Theresa A Guise · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Cancer In the Jerusalem Perinatal Study
$600,585Columbia University Health Sciences · R01 · FY2005 · CA
NCI National Clinical Trials Network-Network Lead Academic Participating Site
$600,573Lawrence E Flaherty · Wayne State University · U10 · FY2017 · CA